Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.

Viktor Rotbain CurovicMorten B HoulindMarjolein Y A M KroonenNiels JongsEmilie H ZobelTine Willum HansenJuliette TavenierJesper Eugen-OlsenGozewijn D LavermanAdriaan KooyFrederik PerssonEllen Burgess Hiddo J Lambers Heerspink

Published in: Diabetes, obesity & metabolism (2023)

We demonstrated no overall effect of 4-week treatment with telmisartan, empagliflozin, linagliptin or baricitinib on suPAR. However, individualization of treatment might significantly reduce suPAR levels.

Keyphrases

type diabetes
cardiovascular disease
clinical trial
combination therapy
study protocol
adverse drug
double blind